Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2006 1
2007 3
2008 6
2009 5
2010 5
2011 2
2012 2
2013 2
2014 3
2015 3
2016 3
2017 3
2018 3
2019 4
2020 7
2021 11
2022 6
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL, Brown F, Long M, Weigel C, Koirala S, Chung JH, Pray B, Villagomez L, Hinterschied C, Sircar A, Helmig-Mason J, Prouty A, Brooks E, Youssef Y, Hanel W, Parekh S, Chan WK, Chen Z, Lapalombella R, Sehgal L, Vaddi K, Scherle P, Chen-Kiang S, Di Liberto M, Elemento O, Meydan C, Foox J, Butler D, Mason CE, Baiocchi RA, Alinari L. Sloan SL, et al. Among authors: lapalombella r. Blood. 2023 Sep 7;142(10):887-902. doi: 10.1182/blood.2022019419. Blood. 2023. PMID: 37267517
Microenvironmental control of hematopoietic stem cell fate via CXCL8 and protein kinase C.
Binder V, Li W, Faisal M, Oyman K, Calkins DL, Shaffer J, Teets EM, Sher S, Magnotte A, Belardo A, Deruelle W, Gregory TC, Orwick S, Hagedorn EJ, Perlin JR, Avagyan S, Lichtig A, Barrett F, Ammerman M, Yang S, Zhou Y, Carson WE, Shive HR, Blachly JS, Lapalombella R, Zon LI, Blaser BW. Binder V, et al. Among authors: lapalombella r. Cell Rep. 2023 May 30;42(5):112528. doi: 10.1016/j.celrep.2023.112528. Epub 2023 May 18. Cell Rep. 2023. PMID: 37209097 Free PMC article.
Selinexor for advanced hematologic malignancies.
Walker JS, Garzon R, Lapalombella R. Walker JS, et al. Among authors: lapalombella r. Leuk Lymphoma. 2020 Oct;61(10):2335-2350. doi: 10.1080/10428194.2020.1775210. Epub 2020 Jun 14. Leuk Lymphoma. 2020. PMID: 32536290 Review.
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.
Hing ZA, Walker JS, Whipp EC, Brinton L, Cannon M, Zhang P, Sher S, Cempre CB, Brown F, Smith PL, Agostinelli C, Pileri SA, Skinner JN, Williams K, Phillips H, Shaffer J, Beaver LP, Pan A, Shin K, Gregory CT, Ozer GH, Yilmaz SA, Harrington BK, Lehman AM, Yu L, Coppola V, Yan P, Scherle P, Wang M, Pitis P, Xu C, Vaddi K, Chen-Kiang S, Woyach J, Blachly JS, Alinari L, Yang Y, Byrd JC, Baiocchi RA, Blaser BW, Lapalombella R. Hing ZA, et al. Among authors: lapalombella r. Nat Commun. 2023 Jan 6;14(1):97. doi: 10.1038/s41467-022-35778-1. Nat Commun. 2023. PMID: 36609611 Free PMC article.
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis.
Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, Luskin MR, Knepper TC, Wanjari P, Wang P, Lager AM, Fitzpatrick C, Segal JP, Gharghabi M, Gurbuxani S, Venkataraman G, Cheng JX, Eisfelder BJ, Bohorquez O, Patel AA, Umesh Nagalakshmi S, Jayaram S, Odenike OM, Larson RA, Godley LA, Arber DA, Gibson CJ, Munshi NC, Marcucci G, Ebert BL, Greally JM, Steidl U, Lapalombella R, Shah BD, Stock W. Saygin C, et al. Among authors: lapalombella r. Blood Cancer Discov. 2023 Dec 27. doi: 10.1158/2643-3230.BCD-23-0106. Online ahead of print. Blood Cancer Discov. 2023. PMID: 38150184
Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor-mediated synergistic antileukemic actions.
Zhang P, Brinton LT, Gharghabi M, Sher S, Williams K, Cannon M, Walker JS, Canfield D, Beaver L, Cempre CB, Phillips H, Chen X, Yan P, Lehman A, Scherle P, Wang M, Vaddi K, Baiocchi R, Wang R, Sampath D, Alinari L, Blachly JS, Lapalombella R. Zhang P, et al. Among authors: lapalombella r. Sci Adv. 2022 Sep 16;8(37):eabp9005. doi: 10.1126/sciadv.abp9005. Epub 2022 Sep 16. Sci Adv. 2022. PMID: 36112677 Free PMC article.
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason J, Long M, Chan WK, Prouty A, Chung JH, Zhang Y, Singh S, Youssef Y, Bhagwat N, Chen Z, Chen-Kiang S, Di Liberto M, Elemento O, Sehgal L, Alinari L, Vaddi K, Scherle P, Lapalombella R, Paik J, Baiocchi RA. Brown-Burke F, et al. Among authors: lapalombella r. Blood Adv. 2023 Oct 24;7(20):6211-6224. doi: 10.1182/bloodadvances.2023009906. Blood Adv. 2023. PMID: 37327122 Free PMC article.
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R. Sher S, et al. Among authors: lapalombella r. Leukemia. 2023 Feb;37(2):326-338. doi: 10.1038/s41375-022-01758-z. Epub 2022 Nov 14. Leukemia. 2023. PMID: 36376377 Free PMC article.
Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
Zhang P, Brinton LT, Williams K, Sher S, Orwick S, Tzung-Huei L, Mims AS, Coss CC, Kulp SK, Youssef Y, Chan WK, Mitchell S, Mustonen A, Cannon M, Phillips H, Lehman AM, Kauffman T, Beaver L, Canfield D, Grieselhuber NR, Alinari L, Sampath D, Yan P, Byrd JC, Blachly JS, Lapalombella R. Zhang P, et al. Among authors: lapalombella r. Clin Cancer Res. 2021 Apr 15;27(8):2352-2366. doi: 10.1158/1078-0432.CCR-20-3724. Epub 2021 Feb 4. Clin Cancer Res. 2021. PMID: 33542077 Free PMC article.
74 results